

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Cost Comparison Appraisal**


## **Eplontersen for treating hereditary transthyretin amyloidosis [ID6337]**

## **Final Stakeholder List**

Consultees	Commentators (no right to submit or appeal)
Company	General
<ul> <li>AstraZeneca (eplontersen)</li> <li>Patient/carer groups</li> <li>Addenbrookes Liver Transplant Association</li> <li>Arrythmia Alliance</li> </ul>	<ul> <li>All Wales Inherited Metabolic Disease Service</li> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Association of Renal Industries</li> </ul>
<ul><li>Atrial Fibrillation Association</li><li>British Liver Trust</li><li>Cardiomyopathy UK</li></ul>	<ul><li>Board of Community Health Councils in Wales</li><li>British National Formulary</li></ul>
<ul> <li>Cardiomyopathy or</li> <li>Cardiovascular Care Partnership</li> <li>Gene People</li> <li>Genetic Alliance UK</li> <li>HEART UK</li> <li>Liver4Life</li> <li>Somerville Foundation</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>UK ATTR Amyloidosis Patients Association</li> <li>Healthcare professional groups</li> <li>Association of British Neurologists</li> <li>Association of Genetic Nurses and Counsellors</li> <li>Association of Renal Technologists</li> </ul>	<ul> <li>Care Quality Commission</li> <li>Cell and Gene Therapy Catapult</li> <li>Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>National Services Division</li> <li>Scottish Society of Gastroenterology</li> <li>NHS Confederation</li> <li>Scottish Medicines Consortium</li> <li>Wales Neurological Alliance</li> <li>Welsh Government</li> <li>Welsh Health Specialised Services</li> </ul>
British Association for the Study of the Liver	Committee
<ul> <li>British Association of Endocrine and Thyroid Surgeons</li> <li>British Association of Urological</li> </ul>	<ul><li>Comparator companies</li><li>Alnylam (patisiran, vutrisiran)</li><li>Akcea Therapeutics (inotersen)</li></ul>
<ul><li>Nurses</li><li>British Association of Urological Surgeons</li></ul>	Relevant research groups  Brain Research UK
<ul><li>British Cardiovascular Society</li><li>British Geriatrics Society</li></ul>	<ul><li>Circulation Foundation</li><li>Cochrane UK</li></ul>

Final stakeholder list for the appraisal of eplontersen for treating hereditary transthyretin amyloidosis [ID6337]

Issue date: January 2024




### Consultees Commentators (no right to submit or appeal) **British Neuropathological Society** Cochrane Hepato-Biliary Group British Society for Gene and Cell Cochrane Metabolic & Endocrine Therapy **Disorders Group** • Foundation for Liver Research **British Society for Genetic Medicine** British Society of Gastroenterology Genomics England British Society of Paediatric MRC Clinical Trials Unit Gastroenterology, Hepatology and National Centre for Cardiovascular Nutrition **Preventions and Outcomes** Institute of Neurology National Hospital for Neurology and National Heart and Lung Institute Neurosurgery National Metabolic Biochemistry National Institute for Health Research Network National Neuroscience Advisory Associated Public Health groups Group **Public Health Wales** Neuromodulation Society of UK and Ireland **UK Health Security Agency Primary Care and Community Neurology Society** Primary Care Cardiovascular Society Primary Care Society for Gastroenterology Royal College of General Practitioners Royal College of Nursing Royal College of Ophthalmologists Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine Society for Endocrinology **UK Clinical Pharmacy Association** Vascular Society of Great Britain and Ireland **Others** National Amyloidosis Centre, UCL Department of Health and Social Care NHS England

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Final stakeholder list for the appraisal of eplontersen for treating hereditary transthyretin amyloidosis [ID6337]

Issue date: January 2024



#### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.